Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomics of Risperidone in Autism
NCT00584701Phase 3
Key facts
- Status
- Completed
- Start
- Jan 2008
- Primary completion
- May 2009
- Countries
- 1
- Sponsor
- University of California, San Francisco
- Modality
- Small Molecules
- Drugs
- risperidone
- Conditions
- Autism Spectrum Disorder (ASD)
01
Overview
Phase 3, open-label, single-arm trial of risperidone in Autism Spectrum Disorder (ASD), sponsored by University of California, San Francisco. Primary endpoint: Aberrant Behavior Checklist - Irritability Subscale at 8 weeks. Started Jan 2008; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Risperidone
Open-label risperidone treatment.
03
Endpoints
Primary
Aberrant Behavior Checklist - Irritability Subscale
Secondary
Exon Expression Correlation with ABC-I Improvement
Beyond the preview
Go deeper on NCT00584701.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00584701.